[{"orgOrder":0,"company":"IntelGenx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ ATAI Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"IntelGenx \/ ATAI Life Sciences"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tilray","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Tilray","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Tilray"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntelGenx \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Tetra BioPharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"Cysteinyl leukotriene receptor 1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ IntelGenx"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor | Kappa opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Digital Offering, LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Digital Offering, LLC","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Digital Offering, LLC"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ IntelGenx"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cantone Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Cantone Research","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Cantone Research"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Exeltis"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Gensco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Gensco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Gensco Pharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Undisclosed"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Gensco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Gensco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Gensco Pharma"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntelGenx \/ Cybin","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx \/ Cybin"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Loxapine","moa":"Serotonin 2c (5-HT2c) receptor | D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IntelGenx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IntelGenx \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by IntelGenx
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
